Peer-influenced content. Sources you trust. No registration required. This is HCN.

Journal of Clinical OncologyRandomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984

Cediranib plus olaparib improved rPFS in men with mCRPC compared to olaparib alone. This combination was linked to an increase in the occurrence of grade 3-4 adverse events. BRCA2-mutated subgroups receiving olaparib with or without cediranib had a numerically longer median rPFS.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form